arrow
E

Emre Yekedüz

Dana-Farber Cancer Institute
H指数:13
被引数:616

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

60 Germline Platelet Polygenic Risk Score Predicts Renal Cell Carcinoma Survival via Sustained Thrombocytosis

60 生殖系血小板多基因风险评分通过持续性血小板增多预测肾细胞癌生存

2026-09-020
OAAI
Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Gustave Roussy免疫评分对接受一线免疫疗法为基础的联合治疗转移性肾细胞癌的预后影响:土耳其肿瘤学组肾癌联盟(TKCC)的研究结果

2026-08-060
OA
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

尿酸盐水平在转移性肾细胞癌接受纳武利尤单抗治疗中的研究:一项土耳其肿瘤学组肾癌联盟(TKCC)研究

2025-07-030
PRE
Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials

对转移性去势敏感前列腺癌患者生存结局的影响:一项随机III期临床试验的Meta分析

2025-05-010
PRE
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

在转移性肾细胞癌中 navigat ing二线疗法:免疫检查点抑制剂与酪氨酸激酶抑制剂的比较分析:土耳其肿瘤学组肾癌联盟的研究

2025-04-240
OA
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

舒尼替尼在转移性肾细胞癌中的应用:土耳其肿瘤学组肾癌协作组中不同风险组的临床结局

2025-02-101
OAAI
ERBB2 amplifications across sex, race, and cancer types

ERBB2扩增在性别、种族和癌症类型间的分布

2024-09-010
PRE
Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens

基线放射学肿瘤负荷(BRTB)与接受一线(1L)免疫治疗(IO)方案治疗的转移性透明细胞肾细胞癌(mccRCC)患者预后的关系

2024-09-010
PRE
The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

镥-177 PSMA-617放射配体治疗转移性去势抵抗性前列腺癌的真实世界结果: 土耳其肿瘤学组多中心研究

2023-10-1110
OA
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
2022-10-0311
OAAI